Protein Assays & Characterization - The Official Blog for All Things NanoTemper

NanoTemper Technologies announces Monolith X with breakthrough Spectral Shift technology, enabling binding affinity measurements where other methods fail 

September 21, 2022

NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.

August 8, 2022

As a gene therapy scientist, you face an abundance of challenges when working to build…

May 18, 2022

MUNICH, Germany, 18 May 2022 — NanoTemper Technologies, well-known for creating biophysical tools that tackle…

May 12, 2022

With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important…

May 12, 2022

With so much interest and investment in target protein degradation, a lot can happen in…

April 6, 2022

MUNICH/DRESDEN, April 6, 2022—NanoTemper Technologies, in partnership with PharmAI, announced the launch of Proto, a…

March 31, 2022

Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise…

March 24, 2022

NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built…

February 16, 2022

SOUTH SAN FRANCISCO, Calif Feb 16 2022 — NanoTemper Technologies today announced the addition of…

November 4, 2021

Reproducibility is a key tenet of scientific research, but many pharma groups have projects that…